Siddiqui Wasim Ahmed, Al Salmi Issa, Jha Amitabh, Pakkyara Abbas, Yasir Mohammad, Shaheen Faissal A M
Department of Renal Medicine, The Royal Hospital, Muscat, Oman.
The Saudi Center for Organ Transplantation, Riyadh, Saudi Arabia.
Saudi J Kidney Dis Transpl. 2017 Jul-Aug;28(4):774-781.
Cytomegalovirus (CMV) is one of the most frequently encountered opportunistic viral pathogens in kidney transplant recipients. In this study, we retrospectively reviewed all living related and unrelated kidney transplant recipients on regular follow-up from January 2006 to June 2015, who were suspected to have CMV clinically and confirmed by DNA polymerase chain reaction (PCR). CMV PCR was detected in 102 kidney transplant recipients. The median time of detection after kidney transplant was 21 months, ranging from 15 days to 84 months. There were 58 male and 44 female patients. The induction immunosuppression in living related kidney transplants was with antithymocyte globulin or basiliximab, whereas the most common maintenance immunosuppressive regimen was with cyclosporine, mycophenolate mofetil, and prednisolone. Most of the transplant recipients were asymptomatic at the time of detection of CMV PCR (67%). Fever, mainly low grade, was the main presentation in 16% of patients, followed by diarrhea (15%) and pneumonitis (2%). The most common hematological abnormality was lymphopenia seen in 46% of patients, followed by anemia (40%) and thrombocytopenia (14%). The common biochemical abnormalities found were elevated alanine aminotransaminase (18%) and hyperbilirubinemia (9%). The serum creatinine was found to be above baseline in 72% of patients. All patients with CMV infection were treated with intravenous ganciclovir, 2.5-5 mg/kg q 12 hourly, according to creatinine clearance, for 21 days. The treatment was successful in all but two patients, who died during the treatment period. There was a significant improvement in the kidney and liver functions after successful treatment of CMV infection. Our study shows that CMV infection should be considered in a patient presenting with unexplained rise in serum creatinine, low-grade fever, diarrhea, or anemia. A significant improvement in kidney and liver functions was observed after successful treatment of the infection.
巨细胞病毒(CMV)是肾移植受者中最常见的机会性病毒病原体之一。在本研究中,我们回顾性分析了2006年1月至2015年6月期间所有定期随访的亲属活体肾移植和非亲属活体肾移植受者,这些受者临床上怀疑感染CMV且经DNA聚合酶链反应(PCR)确诊。102例肾移植受者检测到CMV PCR。肾移植后检测到CMV的中位时间为21个月,范围为15天至84个月。有58例男性和44例女性患者。亲属活体肾移植的诱导免疫抑制采用抗胸腺细胞球蛋白或巴利昔单抗,而最常见的维持免疫抑制方案是环孢素、霉酚酸酯和泼尼松龙。大多数移植受者在检测到CMV PCR时无症状(67%)。发热,主要为低热,是16%患者的主要表现,其次是腹泻(15%)和肺炎(2%)。最常见的血液学异常是淋巴细胞减少,见于46%的患者,其次是贫血(40%)和血小板减少(14%)。常见的生化异常是丙氨酸氨基转移酶升高(18%)和高胆红素血症(9%)。72%的患者血清肌酐高于基线水平。所有CMV感染患者均根据肌酐清除率静脉注射更昔洛韦,2.5 - 5mg/kg,每12小时一次,共21天。除两名在治疗期间死亡的患者外,所有患者治疗均成功。CMV感染成功治疗后,肾和肝功能有显著改善。我们的研究表明,对于血清肌酐不明原因升高、低热、腹泻或贫血的患者应考虑CMV感染。感染成功治疗后观察到肾和肝功能有显著改善。